Edwards Lifesciences

Paul Eccles Joins Basis as Managing Partner to Lead Consultancy's Health Division

Retrieved on: 
Wednesday, September 28, 2022
Health, Culture, Molecular biology, Partner, University, Growth, CPG, Industry, Strategic Advisory Group of Experts, Forecasting, Patient, Edwards Lifesciences, Doctor of Philosophy, Research, Brunel University London, Financial services, Management, Basis

NEW YORK, Sept. 28, 2022 /PRNewswire/ -- Basis , a global strategy and insight consultancy headquartered in London with offices in New York City, Los Angeles and Chicago has named Paul Eccles as Managing Partner of Basis Health in New York.

Key Points: 
  • NEW YORK, Sept. 28, 2022 /PRNewswire/ -- Basis , a global strategy and insight consultancy headquartered in London with offices in New York City, Los Angeles and Chicago has named Paul Eccles as Managing Partner of Basis Health in New York.
  • The announcement comes as the company continues its rapid growth and commercialization in its health division, Basis Health .
  • "As we continue to grow Basis Health, adding Paul to the team only strengthens our commitment to invest and deliver thoughtful and strategic guidance to our people, partners and clients."
  • Basis Health partners with LifeScience companies to inform and drive strategic decisions, powered by research and analytics, supporting across an expansive range of business needs and therapeutic areas.

EDWARDS ANNOUNCES SIX-MONTH DATA CONFIRMING TEER AS SAFE AND EFFECTIVE FOR DMR IN FIRST HEAD-TO-HEAD TRIAL

Retrieved on: 
Saturday, September 17, 2022
Linda, Safety, Edwards Lifesciences, Quality of life, Alfieri, Critical care, U.S. Securities and Exchange Commission, Ventricular remodeling, MitraClip, Significance, CLASP, Drug Quality and Security Act, Annual report, DMR, View, YouTube, PASCAL, NYSE, MD, Quality, CE marking, News, Forward-looking statement, Instagram, Edwards, Security (finance), Transcatheter arterial chemoembolization, Mitral valve, Risk, Securities Exchange Act of 1934, Adrenal insufficiency, Twitter, LinkedIn, Securities Act of 1933, Stroke, Structural heart disease, Randomized controlled trial, Multimedia, University, TCT, Pharmaceutical industry, Medical imaging, Medical device, Patient, Facebook

The study confirms TEER as a safe and effective therapy in patients with degenerative mitral regurgitation (DMR).

Key Points: 
  • The study confirms TEER as a safe and effective therapy in patients with degenerative mitral regurgitation (DMR).
  • The PASCAL system further demonstrated significant and sustained MR 1+ with 83.7 percent of patients at MR 1+ at six months.
  • The CLASP IID trial is a prospective randomized controlled trial comparing the safety and effectiveness of the PASCAL system to the MitraClip system.
  • Edwards, Edwards Lifesciences, the stylized E logo, CLASP, Edwards PASCAL, Edwards PASCAL Precision, PASCAL, and PASCAL Precision are trademarks of Edwards Lifesciences Corporation.

EDWARDS PASCAL PRECISION TRANSCATHETER VALVE REPAIR SYSTEM RECEIVES FDA APPROVAL FOR DEGENERATIVE MITRAL REGURGITATION

Retrieved on: 
Thursday, September 15, 2022
YouTube, Securities Exchange Act of 1934, Adrenal insufficiency, PASCAL, Safety, Twitter, NYSE, Oregon Health & Science University, FDA, CLASP, Drug Quality and Security Act, TVT, Edwards Lifesciences, Division, LinkedIn, CE marking, News, Alfieri, Securities Act of 1933, U.S. Securities and Exchange Commission, Critical care, Patient, Forward-looking statement, History, Medical school, Instagram, Annual report, DMR, Leadership, TCT, Randomized controlled trial, Associate, Security (finance), Multimedia, Oregon Health and Science University Center for Women's Health, School, View, Mitral valve, Pharmaceutical industry, Medical device, Facebook

IRVINE, Calif., Sept. 15, 2022 /PRNewswire/ --Edwards Lifesciences Corporation (NYSE: EW), today announced the company's PASCAL Precision transcathetervalve repair system for transcatheter edge-to-edge repair (TEER) has received FDA approval for the treatment of patients with degenerative mitral regurgitation (DMR).

Key Points: 
  • IRVINE, Calif., Sept. 15, 2022 /PRNewswire/ --Edwards Lifesciences Corporation (NYSE: EW), today announced the company's PASCAL Precision transcathetervalve repair system for transcatheter edge-to-edge repair (TEER) has received FDA approval for the treatment of patients with degenerative mitral regurgitation (DMR).
  • With FDA approval of the PASCAL system, US clinicians now have an additional option for treating patients with severe mitral regurgitation."
  • Transcatheter Edge-to-Edge Repair (TEER) of the mitral valve isused in the treatment of mitral regurgitation.
  • Edwards, Edwards Lifesciences, the stylized E logo, CLASP, Edwards PASCAL, Edwards PASCAL Precision, PASCAL, and PASCAL Precision are trademarks of Edwards Lifesciences Corporation.

Pure Sunfarms Pink Kush is Ontario’s All-Time Top-Selling Strain

Retrieved on: 
Wednesday, September 14, 2022
Cream, Ginger, CBD, OCS, Industry, CEO, Nasdaq, Cannabis, Edwards Lifesciences, ROSE, Heart, GLOBE, Plant, Delta 3 greenhouse, Drug, EU

Originally offered by Pure Sunfarms in June 2020, Pink Kush represents nearly 6 per cent market share since its launch in the dried flower category at the OCS, outperforming the second ranked strain three to one.

Key Points: 
  • Originally offered by Pure Sunfarms in June 2020, Pink Kush represents nearly 6 per cent market share since its launch in the dried flower category at the OCS, outperforming the second ranked strain three to one.
  • We are intentional about cultivation at Pure Sunfarms our growers really know how to bring the best out of our Pink Kush.
  • In addition to Pure Sunfarms Pink Kush, one of the companys newest innovation strains, Jet Fuel Gelato, is adding to Pure Sunfarms dried flower market share performance at the OCS as the fastest-growing strain.
  • Pure Sunfarms is the licensed producer of record for Pure Sunfarms, The Original Fraser Valley Weed Co. and is Cookies sun-grown partner in Canada.

Epic Launches Life Sciences Program, Unifying Clinical Research with Care Delivery

Retrieved on: 
Wednesday, September 14, 2022
Cosmos, Clinical trial, Research, List of life sciences, Organization, Friction, News, Epic, Patient, CRO, Multimedia, Efficiency, Edwards Lifesciences, View, Program, Reliance Institute of Life Sciences, Pharmaceutical industry, Online shopping

VERONA, Wis., Sept. 14, 2022 /PRNewswire/ -- Epic announces the release of its Life Sciences program, expanding its work to bring together the disconnected parts of healthcare. The program is built to help providers, pharmaceutical companies, and medical device manufacturers recruit research participants, expand clinical trial access to underrepresented communities, and speed up the development of new therapies.

Key Points: 
  • "The Life Sciences program is designed to create a seamless connection between participant patients, healthcare providers, and research sponsors through the use of a single system," said Alan Hutchison, vice president at Epic.
  • "Unifying clinical research with care delivery and building a direct connection to study sponsors will help accelerate the development of new therapies by making studies more efficient, more accessible, and more effective."
  • "The first stage of the Life Sciences program, clinical trial matchmaking, is available today and provider organizations in the Epic community are already signing up," said Seth Howard, vice president of research and development at Epic.
  • Provider organizations in the Epic community and life sciences groups that are interested in study feasibility and clinical trial matchmaking can reach out to [email protected] to learn more.

EDWARDS LAUNCHES SAPIEN 3 ULTRA RESILIA VALVE FOLLOWING FDA APPROVAL

Retrieved on: 
Monday, September 12, 2022
YouTube, Securities Exchange Act of 1934, Safety, Valve, Twitter, NYSE, FDA, Food, Securities Act of 1933, Edwards Lifesciences, LinkedIn, News, Industry, Forward-looking statement, U.S. Securities and Exchange Commission, Critical care, Patient, Instagram, Leadership, Science, Edwards, Security (finance), Ultra, Multimedia, Aortic valve, Food and Drug Administration, View, Freedom, Pharmaceutical industry, Medical imaging, Facebook

IRVINE, Calif., Sept. 12, 2022 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today announced the launch of the SAPIEN 3 Ultra RESILIA valve, which incorporates Edwards' breakthrough RESILIA tissue technology with the industry-leading SAPIEN 3 Ultra transcatheter aortic heart valve.

Key Points: 
  • IRVINE, Calif., Sept. 12, 2022 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today announced the launch of the SAPIEN 3 Ultra RESILIA valve, which incorporates Edwards' breakthrough RESILIA tissue technology with the industry-leading SAPIEN 3 Ultra transcatheter aortic heart valve.
  • RESILIA tissue has demonstrated freedom from structural valve deterioration at 5 years and provides the potential to extend the durability of the SAPIEN 3 Ultra RESILIA valve.
  • "The SAPIEN 3 Ultra RESILIA valve builds on Edwards' 40 years of leadership in tissue technology by combining advancements in tissue science with the industry leading SAPIEN 3 Ultra valve to offer the only dry storage transcatheter heart valve on the U.S. market today," said Larry Wood, corporate vice president, transcatheter aortic valve replacement.
  • Edwards, Edwards Lifesciences, the stylized E logo, Edwards SAPIEN, Edwards SAPIEN 3, Edwards SAPIEN 3 Ultra, Edwards SAPIEN 3 Ultra RESILIA, Edwards INSPIRIS RESILIA, INSPIRIS RESILIA, INSPIRIS, RESILIA, SAPIEN, SAPIEN 3, SAPIEN 3 Ultra, and SAPIEN 3 Ultra RESILIA are trademarks of Edwards Lifesciences Corporation.

BD Promotes Two Senior Executives to Segment Leadership Roles

Retrieved on: 
Thursday, August 25, 2022
Medication, Becton, Dickinson and Company headquarters, Patient, University, CEO, Safety, NYSE, Biological engineering, University of Washington Department of Global Health, Technology, Bard, Campion, Surgery, Solution, Becton, MMS, Disease, R, Garrison, Medicine, MDS, Electricity, Mechanical, LinkedIn, EVP, Stevens Institute of Technology, Duke University, BD (company), BD, Organization, Intervention, Therapy, Company, D, Twitter, Edwards Lifesciences, Roche Diagnostics, Efficiency, BDX, Mechanical engineering, Growth, Health, Acquisition, Research and development, Management, Computer data storage, Industrial design, Dentistry, Virginia Tech, Research, Science

They will be members of the BD Executive Leadership Team and report to Tom Polen, chairman, CEO and president of BD.

Key Points: 
  • They will be members of the BD Executive Leadership Team and report to Tom Polen, chairman, CEO and president of BD.
  • In addition, BD announced that Simon Campion will depart the company on Sept. 9 for an executive role in the health care industry.
  • Campion joined BD through the acquisition of Bard and led BD's Interventional segment through the integration.
  • He also served in a number of R&D roles focused on innovation, including vice president of worldwide R&D within BD Medical.

Clinovo taps Life Sciences executive Nandish Poluru as its next Chief Executive Officer

Retrieved on: 
Thursday, August 18, 2022
Laboratory, Forest Laboratories, Electrical engineering, Operations and technology management, Drug, Technology, Growth, Clinical, Health, Cleveland State University, Information, Master, Bristol Myers Squibb, BMS, SAN, Foundation, Research and development, Globe, Sri Venkateswara University, Yale School of Management, List of life sciences, Research, Clinical data management, MBA, University, Regulation, Digital health, Development, Clinical research, Pharmaceutical industry, Management, Silicon, Biostatistics, Allergan, Edwards Lifesciences, Nandish Sandhu, Pharmacovigilance

SAN JOSE, Calif., Aug. 18, 2022 /PRNewswire/ -- Clinovo, a technology focused Clinical services provider that accelerates Clinical Development for Life Sciences industry appoints Nandish Poluru as Chief Executive Officer effective immediately.

Key Points: 
  • SAN JOSE, Calif., Aug. 18, 2022 /PRNewswire/ -- Clinovo, a technology focused Clinical services provider that accelerates Clinical Development for Life Sciences industry appoints Nandish Poluru as Chief Executive Officer effective immediately.
  • Prior to BMS, Nandish was Executive Director at Allergan (an Abbvie company) and worked at Forest Laboratories in various roles.
  • "It is with great excitement and immense pleasure that I welcome Nandish to Clinovo" said Vamsi Maddipatla, President and Chairman at Clinovo.
  • Clinovo works with life sciences customers across the globe to accelerate clinical development and bring new medicines to market faster.

Enzychem Lifesciences Announces Poster Presentation of EC-18 at the Radiation Research Society 2022 Annual Meeting

Retrieved on: 
Monday, July 25, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, KOSDAQ, CEO, Annual general meeting, Polish Radiation Research Society, Homeostasis, RRS, Inflammation, Edwards Lifesciences, Patient, Pharmaceutical industry

Enzychem Lifesciences (KOSDAQ: 183490), a late-stage biopharmaceutical company, announced today the acceptance of a poster presentation at the Radiation Research Society (RRS) 2022 Annual Meeting, which will be held in Waikoloa, Hawaii on October 16-19, 2022.

Key Points: 
  • Enzychem Lifesciences (KOSDAQ: 183490), a late-stage biopharmaceutical company, announced today the acceptance of a poster presentation at the Radiation Research Society (RRS) 2022 Annual Meeting, which will be held in Waikoloa, Hawaii on October 16-19, 2022.
  • The abstract highlights the radio-mitigative potential of its lead investigational compound, EC-18 in gastrointestinal acute radiation syndrome.
  • The details of the presentation are as follows:
    We are excited to present our results at the 2022 RRS conference, that support EC-18s unique mechanism of action to potentially treat gastrointestinal acute radiation syndrome, said Ki Young Sohn, CEO & Chairman of Enzychem Lifesciences.
  • Enzychem Lifesciences (KOSDAQ: 183490) is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies for patients with unmet medical needs in oncology, metabolic and inflammatory diseases.

EDWARDS LIFESCIENCES TO HOST EARNINGS CONFERENCE CALL ON JULY 28, 2022

Retrieved on: 
Thursday, July 21, 2022
Investor relations, Edwards Lifesciences, NYSE, YouTube, Patient, Edwards, Twitter, Instagram, Critical care, LinkedIn, Pharmaceutical industry, Facebook

IRVINE, Calif., July 21, 2022 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended June 30, 2022 after the market closes on Thursday, July 28, 2022, and will host a conference call at 5:00 p.m.

Key Points: 
  • IRVINE, Calif., July 21, 2022 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) plans to announce its operating results for the quarter ended June 30, 2022 after the market closes on Thursday, July 28, 2022, and will host a conference call at 5:00 p.m.
  • The call will also be available live and archived on the "Investor Relations" section of the Edwards website at ir.edwards.com .
  • Edwards Lifesciences, is the global leader of patient-focused innovations for structural heart disease and critical care monitoring.
  • Edwards, Edwards Lifesciences, and the stylized E logo are trademarks of Edwards Lifesciences Corporation.